Nemaura Medical, Inc. (NASDAQ:NMRD) has announced the appointment of Jay L. Warner, a 30-year veteran of the healthcare industry, as its head of US commercial operations.
“Jay brings a wealth of experience to Nemaura, including his experience in developing and commercializing wearable devices applicable to the diabetes market. He has spent a significant portion of his career in that market, providing a solid understanding of the specific needs associated with wearable devices. In addition, he brings the strong relationships that he has built with U.S.-based insurers, which we believe will help to drive the company’s success,” said Faz Chowdhury, Nemaura’s CEO in. statement.
"We are at an important inflection point of the company, as telemedicine platforms such as Livongo and app-based wellness have become more and more ubiquitous since the advent of COVID-19. However, fewer than one million of the more than 25 million people with diabetes are being adequately managed utilizing such services, providing an important and significant opportunity for our clinically proven program, BEATdiabetes.life to not only impact those lives, but 90 million pre-diabetics, the majority of whom may not have adequate support.”
READ: Nemaura Medical announces official US launch of flagship program BEATdiabetes and availability of glucose monitor proBEAT
Prior to joining Nemaura, Warner served as senior vice president of clinical and commercialization at Cequr Corporation, where he oversaw the clinical development and commercialization of two three-day wearable insulin delivery devices. He also spent 17 years at Eli Lilly in increased levels of responsibility, working as U.S. Brand Leader for Byetta, US. and global endocrine director of market research, among other roles.
“Nemaura is a truly unique company that has utilized more than 12 years of clinical evidence to create a user-friendly, measurable approach to managing diabetes that integrates both behavioral modification and a wearable, disposable device that allows the impact of glucose trends to be utilized in diabetes management in a flexible and cost-efficient manner. I’m looking forward to collaborating with the team to make the BEATdiabetes program a success in the United States market,” Warner commented.
Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT and proBEAT.
sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to rthe US Food & Drug Administration (FDA).
proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is expected to be launched in the US as a general wellness product.
The company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
Contact the author at jon.hopkins@proactiveinvestors.com